Masto Peptide CS China Suppliers High Purity Weight Loss Peptide Factory

Buy high-purity Masto peptide CS from leading China suppliers. Our factory provides this innovative GCG GLP-1 dual receptor agonist for effective type 2 diabetes glycemic control and long-term weight management via weekly subcutaneous injection.

SupplierGlobal Technology Co., Ltd.www.hqtechtirz.com

View on supplier website More from this supplier

Source categories

Hot Products

About this product

Product information from the supplier.

Product Overview

Masto peptide CS represents a breakthrough in metabolic regulation, utilizing a dual-action mechanism that synergizes GLP-1R and GCG-R pathways. By suppressing appetite and slowing gastric emptying while simultaneously accelerating fat breakdown and oxidation, it provides a comprehensive solution for weight management and visceral fat reduction.

Engineered for high efficacy, this pharmaceutical-grade peptide is primarily indicated for individuals with a BMI ≥ 28 kg/m², or those with a BMI ≥ 24 kg/m² struggling with metabolic complications such as hyperglycemia and fatty liver. It offers a sophisticated approach to glycemic control for type 2 diabetes patients, combining potency with a structured titration protocol for optimal safety.

Detailed Parameters

Core Mechanisms	GLP-1R & GCG-R Synergism	Primary Indication	Weight Loss & Glycemic Control
Target BMI (General)	≥ 28 kg/m²	Target BMI (Comorbid)	≥ 24 kg/m²
Starting Dosage	2 mg once weekly	Maintenance Dosage	4 mg to 6 mg weekly
Administration	Subcutaneous Injection	Preferred Site	Abdomen, Upper Arm, or Thigh
Key Metric	Up to 14.84% Weight Loss	Clinical Effect	Reduced Visceral Fat & HbA1c

Key Advantages

Dual-Target Synergy

Simultaneous appetite suppression and accelerated fat oxidation for maximum efficiency.

Weekly Administration

Once-weekly dosing schedule simplifies patient compliance and long-term management.

Superior HbA1c Lowering

Outperforms single-target drugs in managing blood glucose levels for type 2 diabetes.

Visceral Fat Reduction

Significantly reduces waist circumference and liver lipids to combat fatty liver disease.

Controlled Titration

Gradual dose escalation minimizes gastrointestinal side effects for better tolerance.

High Pure Grade

Manufactured under strict pharmaceutical standards to ensure purity and biological activity.

Product Gallery

Management Platforms

API Sourcing

Secure procurement of high-purity pharmaceutical intermediates and active peptides.

Quality Control

Rigorous HPLC and MS testing to ensure strict adherence to molecular specifications.

Compliance Monitoring

Ensuring all chemical raw materials meet international pharmaceutical safety standards.

Logistics Tracking

Cold-chain management for peptide stability during global transit.

Inventory Management

Real-time stock updates for popular chemicals and research-grade peptides.

Technical Support

Expert guidance on solubility, storage, and stability for API integration.

Investment Return Comparison

Metric	Single-Target Peptide	Masto Peptide CS
Avg. Weight Loss	5% - 10%	Up to 14.84%
Metabolic Impact	Glucose Reduction Only	Glucose + Lipid Oxidation
Visceral Fat Reduction	Moderate	Significant
Dosing Frequency	Daily/Weekly	Once Weekly
Glycemic Efficacy	Standard	Superior (HbA1c Focus)

Frequently Asked Questions

Q: What is the primary difference between Masto peptide CS and standard GLP-1 agonists?

Unlike standard agonists, Masto peptide CS combines GLP-1R for appetite suppression with GCG-R to accelerate fat breakdown, creating a dual effect of reducing intake and increasing calorie expenditure.

Q: Who are the ideal candidates for this pharmaceutical intermediate?

It is designed for adults with a BMI ≥ 28 kg/m², or those with BMI ≥ 24 kg/m² who have metabolic complications like hypertension, fatty liver, or type 2 diabetes.

Q: How should the dosage be titrated to avoid side effects?

The recommended protocol is starting at 2 mg weekly, increasing to 4 mg after 4 weeks, and finally to 6 mg after another 4 weeks to allow the body to adapt.

Q: What are the common safety contraindications for this product?

It is contraindicated for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Q: How does it impact liver health specifically?

Through the GCG-R mechanism, it helps reduce liver lipids and visceral fat, making it highly effective for managing fatty liver associated with metabolic syndrome.

Q: Can this be used as a monotherapy for type 2 diabetes?

Yes, it can be used as a monotherapy or in combination with oral hypoglycemic agents, though monitoring is required when used in combination therapy to prevent hypoglycemia.